PAP
JBIO

Persistent Asset Partners’s Jade Biosciences JBIO Stock Holding History

Persistent Asset Partners’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,469
Closed -$181K – 343
2025
Q4 		$192K Buy
+12,469
New +$146K 0.09% 215

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Persistent Asset Partners's JBIO Position: Q1 2026 in Review

Persistent Asset Partners sold out of Jade Biosciences (JBIO) in Q1 2026, closing a stake of 12,469 shares — an estimated $181K sold.

Persistent Asset Partners first reported a position in JBIO in Q4 2025 and held it in 1 quarter. The position peaked at $192K in Q4 2025. 120 funds tracked by Wall St. Rank hold JBIO as of Q1 2026.

  • Persistent Asset Partners reported no remaining Jade Biosciences position as of Q1 2026 after selling out during the quarter.
  • Persistent Asset Partners sold 12,469 Jade Biosciences shares in Q1 2026, an estimated $181K.
  • Persistent Asset Partners first reported a position in Jade Biosciences in Q4 2025 and held it in 1 quarter.
  • Persistent Asset Partners's Jade Biosciences position peaked at $192K in Q4 2025.
  • 120 funds tracked by Wall St. Rank held Jade Biosciences as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.